Also found in: Wikipedia.
difluprednate (ophthalmic)(dye-floo-pred-nate) ,
Pregnancy Category: C
ClassificationTherapeutic: ocular agents
Treatment of inflammation and pain associated with ocular surgery.
Decreased pain and inflammation following ocular surgery.
Absorption: Limited systemic absorption.
Metabolism and Excretion: Unknown.
Contraindicated in: Active viral, mycobacterial or fungal infection of eyes and surrounding structures.
Use Cautiously in: Obstetric: Use in pregnancy only if potential benefit justifies potential risk to the fetus; Lactation: Use cautiously during lactation; Pediatric: Safety and effectiveness in children have not been established.
Adverse Reactions/Side Effects
Ear, Eye, Nose, Throat
- ↑ intraocular pressure
- conjunctival hyperemia
- corneal edema
- delayed healing
- eye pain
Drug-Drug interactionNone noted.
Ophthalmic (Adults) 1 drop four times daily, starting 24 hr after surgery for 2 wk, then twice daily for one week, then further tapered based on response.
Ophthamic emulsion: 0.05% in 5 mL bottle
- Assess affected eye for pain and swelling during therapy.
- Monitor intraocular pressure of difluprednate is used more than 10 days.
Potential Nursing DiagnosesAcute pain (Indications)
- Ophthalmic: Instill 1 drop into conjunctival sac of affected eye 4 times/day beginning 24 hrs after surgery and continuing throughout first 2 wks of postoperative period, followed by twice daily for a wk, then base dose on patient response.
- Instruct patient in correct technique and frequency for instillation of eye drops (see ).
- Instruct patient to avoid wearing contact lenses during therapy.
- Advise female patients to notify health care professional if pregnancy is planned or suspected or if breastfeeding.
- Advise patient to notify health care professional if redness, itching or inflammation develops or becomes aggravated.
- Decrease in eye pain and inflammation following ocular surgery.
Drug Guide, © 2015 Farlex and Partners